Healthcare Professionals

Precision oncology approach - CancerTYPE ID® & NeoTYPE® Cancer Profiles together.

Identifying the tumor type is the first step to help determine effective use of genomic alterations and drive optimal treatment.


CancerType ID logo small


An efficient approach to obtain comprehensive information to help you in the treatment of your metastatic patients with unclear diagnoses.

  • Identified a primary tumor type in 98% of cases in a prospective study1
  • Rules out tumor types with 95% confidence
  • 87% accuracy2
  • Profiles available for each CancerTYPE ID tumor type
  • Targeted & actionable multimodal panels with PD-L1
  • Efficient approach delivers comprehensive information
  • Cost effective
  • TMB, MSI, and MMR also available
  • Helps physicians determine a roadmap for therapeutic interventions
  • Tumor-specific chemotherapy, molecular targeted therapies, and immunotherapy or checkpoint inhibitors

"The most important aspect to treating cancer is to know what type of tumor we are dealing with. Once we know this, additional testing like Next Gen Sequencing can help futher stratify treatment approaches, but the fundamental piece of information we need to start with is where the tumor is coming from."

- Andrew Hendifar, MD | Medical Oncologist
   Los Angeles, CA


*NeoTYPE Cancer Profiles are performed and billed separately by our contracted reference laboratory, NeoGenomics Laboratories, Inc.


CancerTYPE ID Indications for Use and Limitations

CancerTYPE ID is indicated for use in tumor specimens from patients diagnosed with malignant disease and is intended to aid in the classification of the tissue of origin and tumor subtype in conjunction with standard clinical and pathological assessment by a qualified physician. CancerTYPE ID is not intended to predict patient survival benefit, treatment efficacy or to distinguish between benign versus malignant lesions. Tumor types not included in the CancerTYPE ID reference database may exhibit RNA expression patterns that are similar to RNA expression patterns within the reference database. This test was developed and performance characteristics have been determined by Biotheranostics, Inc. It has not been cleared or approved by the U.S. Food and Drug Administration. This test is used for clinical purposes. It should not be regarded as investigational or for research. How this information is used to guide patient care is the responsibility of the physician. Biotheranostics is certified under the Clinical Laboratory Improvement Amendments of 1988 as qualified to perform high-complexity clinical laboratory testing.

  1. Hainsworth JD et al. J Clin Oncol, 2013;31:217-23.
  2. Kerr SE et al Clin Cancer Res 2012;18(4):3952-60.